LRRK2 and Parkinson disease: Participants with MC1R + LRRK2 PD (n=187; 2.14; β diff=0.60 (−0.11 to 1.32) p=0.098) exhibited a nominally higher rate of change in MDS-UPDRS III than participants with LRRK2 PD (n=84; 1.54 (0.93 to 2.15)) while participants with MC1R + GBA PD (n=83; 2.39, β diff=−0.60 (−1.92, 0.71) p=0.366) exhibited a nominally lower rate of change in MDS-UPDR III than those with GBA PD (n=43; 2.99 (1.90 to 4.09))(Table 4).